Hemispherx Biopharma has renewed its sales, marketing, distribution and supply agreement for Argentina with GP Pharm Latino America, an affiliate company of Spanish GP Pharm SA. The previous agreement had expired on June 14, 2015. Under this new agreement, GP Pharm will be responsible for gaining regulatory approval in Argentina for Ampligen, an experimental therapeutic, to treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and for commercializing Ampligen for this indication in A...